Assessment of Reproductive and Developmental Toxicity in IND-Enabling Studies
Reproductive and developmental toxicity studies are critical for identifying risks to fertility, embryonic development, and offspring viability. These studies provide essential safety data for compounds intended for chronic use, especially in populations of reproductive age or during pregnancy. For IND-enabling toxicology, the design of reproductive studies is governed by ICH guidelines such as ICH S5(R3), which outline stages of reproductive risk evaluation.
Assessment begins with general toxicity studies that monitor reproductive organ weights, estrous cycling, and histopathology of gonads and accessory sex tissues. If concerns arise or if the compound’s intended use suggests a need, more targeted studies follow. Segment I studies evaluate fertility and early embryonic development, Segment II studies assess embryo–fetal development (teratogenicity), and Segment III studies examine pre- and postnatal development.
Rodent and non-rodent species are typically employed to ensure relevance across taxa. Parameters evaluated include mating performance, implantation rates, fetal resorptions, litter size, external and skeletal malformations, and postnatal growth. Maternal toxicity must be distinguished from developmental toxicity to properly assess causality.
Interpretation of reproductive data requires integration with pharmacokinetic, endocrine, and histological data. A compound’s mechanism of action, placental transfer properties, and maternal metabolism all contribute to fetal exposure and potential developmental outcomes. Studies must be carefully timed to match critical windows of reproductive development in the chosen species.
Incorporating reproductive toxicity studies into the IND package supports comprehensive risk assessment and is often required before enrolling women of childbearing potential in clinical trials.